Bacterial Vaginosis

1. Clinical Overview

Summary

Bacterial Vaginosis (BV) is the most common cause of abnormal vaginal discharge in women of reproductive age, affecting approximately 30% of women globally. [1,2] It represents a polymicrobial dysbiosis (ecological imbalance) rather than a single infection. The condition is characterized by a depletion of protective, hydrogen peroxide (H₂O₂)-producing Lactobacillus species and an overgrowth of anaerobic bacteria including Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and Mobiluncus species. [3,4]

While not strictly classified as a Sexually Transmitted Infection (STI), BV is sexually associated, with increased prevalence among women with new or multiple sexual partners, and particularly high concordance among women who have sex with women (WSW). [5] The condition has significant clinical implications beyond symptomatic discharge, including increased susceptibility to STIs (HIV, HSV-2, Chlamydia), obstetric complications (preterm birth, late miscarriage, postpartum endometritis), and post-procedural infections (post-abortion PID, post-hysterectomy cellulitis). [6,7]

BV is characterized by a paradoxical presentation: while bacterial proliferation is massive, inflammatory signs are minimal or absent (hence "vaginosis" rather than "vaginitis"). This distinguishes it from other causes of vaginal discharge and reflects the unique pathophysiology of biofilm formation rather than tissue invasion. [8]

Clinical Pearls

The "Whiff" Test: Adding 10% Potassium Hydroxide (KOH) to a drop of vaginal discharge volatilizes amines (putrescine and cadaverine), releasing a pungent fishy smell. This is highly specific for BV and can be performed at the bedside with immediate results.

pH is King: Healthy vaginal pH is acidic (3.5-4.5) due to Lactobacilli producing lactic acid from glycogen. In BV, pH rises to >4.5 due to loss of lactobacilli and production of alkaline amines. This is a quick bedside discriminator that distinguishes BV from vulvovaginal candidiasis, which maintains normal acidic pH.

Biofilm Formation: Gardnerella vaginalis forms a tenacious biofilm on the vaginal epithelium, creating a structured bacterial community encased in extracellular matrix. This biofilm protects bacteria from antibiotics and host immune responses, explaining the high rate of recurrence (>50% within 12 months) despite appropriate initial treatment. [9]

Asymptomatic Majority: Approximately 50% of women with BV are asymptomatic, raising important questions about screening, particularly in high-risk populations such as pregnant women or those undergoing gynecological procedures. [10]

---

2. Epidemiology

Global Prevalence

BV is the most prevalent vaginal condition worldwide among women of reproductive age. Prevalence varies significantly by population and geographic region:

Incidence and Demographics

• Annual incidence: Approximately 10-15 per 100 women-years in reproductive-age women [2]
• Peak prevalence: Ages 20-40 years
• Recurrence rate: 30% at 3 months, 50-60% at 12 months after successful treatment [12]
• Symptomatic cases: Only 50% of women with BV report symptoms [10]

Risk Factors

Sexual Behaviors

• New sexual partner (within last 6 months)
• Multiple sexual partners (≥2 in past year)
• Women who have sex with women (WSW) - highest risk group [5]
• Lack of condom use
• Receptive oral sex

Hygiene Practices

• Vaginal douching (odds ratio 2.4) [13]
• Use of alkaline soaps or antiseptics in genital area
• Frequent bubble baths
• Intravaginal products (deodorants, perfumed products)

Demographic Factors

• Black or African-Caribbean ethnicity (2-3× higher risk) [2]
• Cigarette smoking (current smokers: OR 1.7) [13]
• Lower socioeconomic status
• Stress and psychological factors

Medical Factors

• Recent antibiotic use (disrupts lactobacilli)
• Intrauterine device (IUD) use
• Diabetes mellitus (poorly controlled)
• Immunosuppression (HIV infection)

Protective Factors

• Combined oral contraceptive pill (COCP): Estrogen promotes glycogen deposition in vaginal epithelium, which lactobacilli metabolize to lactic acid, maintaining acidic pH (OR 0.6) [13]
• Consistent condom use: Reduces exposure to alkaline seminal fluid
• Lactobacillus-dominant vaginal microbiome (particularly L. crispatus)
• Circumcised male partners: Lower prevalence in some studies

---

3. Aetiology and Pathophysiology

Mechanism of Dysbiosis

BV represents a complex shift from a lactobacillus-dominant ecosystem to a polymicrobial anaerobic community. The pathogenesis involves multiple stages:

Stage 1: Loss of Lactobacillus Defense

The healthy vagina is dominated by Lactobacillus species (particularly L. crispatus, L. jensenii, L. gasseri, and L. iners). These organisms provide protection through multiple mechanisms:

1. Lactic acid production: Metabolizes glycogen from epithelial cells to lactic acid, maintaining pH 3.5-4.5
2. H₂O₂ production: Creates an oxidative environment toxic to anaerobes [3]
3. Bacteriocin production: Antimicrobial peptides that inhibit pathogen adherence
4. Competitive exclusion: Occupies epithelial binding sites, preventing pathogen attachment
5. Immune modulation: Maintains anti-inflammatory vaginal environment

Triggers for lactobacillus depletion include:

• Alkalinization (semen, menstrual blood, douching)
• Antibiotic exposure
• Hormonal changes (low estrogen states)
• Sexual activity (disruption of vaginal ecosystem)

Stage 2: Anaerobic Bacterial Overgrowth

With loss of lactobacillus protection, anaerobic bacteria proliferate exponentially:

Key Organisms:

• Gardnerella vaginalis (present in 95-100% of BV cases) [8]
• Atopobium vaginae (associated with treatment failure and recurrence)
• Prevotella species
• Mobiluncus species (curved rods, associated with severe BV)
• Mycoplasma hominis
• Ureaplasma urealyticum
• Various anaerobic gram-negative rods

Bacterial Concentration: Increases from 10⁷ to 10⁹-10¹¹ organisms/mL of vaginal fluid [8]

Stage 3: Biofilm Formation

Gardnerella vaginalis adheres to vaginal epithelial cells and produces a structured biofilm:

1. Initial adherence: Fimbriae and pili mediate attachment to epithelial cells
2. Scaffold formation: G. vaginalis creates extracellular matrix
3. Multi-species colonization: Other anaerobes integrate into biofilm architecture
4. Maturation: Biofilm thickness increases, creating micro-anaerobic environment [9]

Clinical Implications of Biofilm:

• Physical barrier to antibiotic penetration
• Protected environment for bacterial persistence
• Resistance to host immune clearance
• Explanation for high recurrence rates despite treatment

Stage 4: Metabolic Consequences

Anaerobic bacteria produce enzymes and metabolites that cause clinical manifestations:

Proteolytic Enzymes:

• Sialidase: Cleaves sialic acid from mucin, reducing protective mucus layer
• Prolidase: Breaks down proline-containing proteins
• Result: Epithelial cells lose glycocalyx, creating "clue cells"

Volatile Amines:

• Putrescine, cadaverine, trimethylamine: Produce characteristic fishy odor
• Alkaline pH: Amines raise vaginal pH to >4.5, further inhibiting lactobacilli
• Enhanced volatilization: Addition of alkaline KOH or exposure to semen/menstrual blood intensifies odor

Other Metabolites:

• Short-chain fatty acids (acetate, succinate) replace lactic acid
• Amino acids from protein degradation
• Minimal inflammatory cytokine production (explains absence of inflammation)

Molecular Pathophysiology

Exam Detail: Genomic and Metagenomic Insights:

Modern molecular techniques have revolutionized understanding of BV:

1. Community State Types (CSTs): Five distinct vaginal microbiome states identified:

   • CST I: L. crispatus-dominated (most stable, lowest BV risk)
   • CST II: L. gasseri-dominated
   • CST III: L. iners-dominated (transitional, higher BV risk)
   • CST V: L. jensenii-dominated
   • CST IV: Low lactobacillus, diverse anaerobes (BV state)

2. Bacterial Vaginosis-Associated Bacteria (BVAB): Novel species identified through 16S rRNA sequencing:

   • BVAB1, BVAB2, BVAB3
   • Associated with treatment failure and recurrence
   • Not detected by traditional culture methods

3. Metabolomic Profiling:

   • Elevated amino acids (proline, tyrosine)
   • Increased biogenic amines
   • Reduced lactic acid
   • Altered lipid profiles

4. Immune Evasion Mechanisms:

   • Downregulation of TLR (Toll-like receptor) expression
   • Reduced pro-inflammatory cytokines (IL-1β, IL-8)
   • Impaired neutrophil recruitment
   • Biofilm protection from complement-mediated lysis

---

4. Clinical Presentation

Symptoms

The cardinal symptom of BV is vaginal discharge, but presentation varies widely:

Vaginal Discharge

• Character: Thin, watery, homogeneous (not thick or curdy)
• Color: White, grey, or off-white (occasionally grey-green)
• Consistency: Low viscosity, "milk-like" appearance
• Distribution: Adherent to vaginal walls, coating mucosa
• Volume: Usually moderate; may be profuse in severe cases

Odor

• Quality: Fishy, "amine-like," musty, unpleasant
• Timing: Often worse after intercourse (semen pH 7.2-7.4 volatilizes amines) or menstruation (blood pH 7.4)
• Severity: Variable; may be minimal or socially distressing
• Patient description: "Rotten fish," "musty basement," "metallic"

Associated Symptoms (Less Common)

• Vulvar irritation: Mild, if present (severe itch suggests candidiasis or trichomoniasis)
• Dyspareunia: Occasional, usually superficial
• Dysuria: Rare (external dysuria if discharge contacts urethra)
• Intermenstrual bleeding: Rare; should prompt investigation for other causes

Asymptomatic BV

50% of women with microbiological/microscopic evidence of BV report no symptoms. [10] This raises important clinical questions:

• Screening indications: Pregnant women? Pre-procedure? STI risk?
• Treatment necessity: Debate ongoing; current guidelines recommend treating symptomatic cases only (with exceptions)
• Natural history: Some cases resolve spontaneously; others persist asymptomatically

Signs on Examination

Speculum Examination

• Discharge appearance: Thin, homogeneous coating of vaginal walls
• Distribution: Often pooling in posterior fornix
• Vaginal mucosa: Normal appearance - no erythema, edema, or inflammation
  • This distinguishes BV ("vaginosis") from inflammatory conditions ("vaginitis")
• Cervix: Usually normal; no cervicitis (if present, consider concurrent STI)
• No friability: Mucosa not fragile or prone to contact bleeding

pH Testing (Bedside)

• Use pH paper (range 4.0-6.0) on lateral vaginal wall
• Normal pH: 3.5-4.5
• BV pH: >4.5 (typically 5.0-6.0)
• Timing consideration: Avoid testing during menstruation or within 24h of intercourse (false elevation)

Whiff Test (Bedside)

• Place drop of vaginal discharge on slide
• Add 1-2 drops of 10% potassium hydroxide (KOH)
• Positive result: Immediate release of fishy amine odor
• Specificity: High for BV (also positive in trichomoniasis)

---

5. Differential Diagnosis

Comprehensive Differential for Vaginal Discharge

Key Distinguishing Features

BV vs Candidiasis:

• BV: Thin discharge, fishy odor, pH >4.5, minimal itch, no inflammation
• Candidiasis: Thick curdy discharge, no odor, pH less than 4.5, severe itch, erythema

BV vs Trichomoniasis:

• BV: Grey/white discharge, no inflammation, clue cells
• Trichomoniasis: Frothy yellow-green discharge, strawberry cervix, motile trichomonads, STI (requires partner treatment)

BV vs Physiological Discharge:

• BV: Homogeneous adherent discharge, pH >4.5, positive whiff test
• Physiological: Floccular discharge, pH 3.5-4.5, negative whiff test, varies with cycle

BV vs Cervicitis:

• BV: Vaginal discharge, normal cervix, no inflammation
• Cervicitis: Mucopurulent cervical discharge, cervical friability, require STI testing

Red Flag Features Suggesting Alternative Diagnosis

• Severe pelvic pain: PID, ectopic pregnancy, ovarian pathology
• Abnormal bleeding: Cervical pathology, endometrial pathology, malignancy
• Severe inflammation: Trichomoniasis, severe candidiasis, desquamative vaginitis
• Dyspareunia: Deep dyspareunia suggests pelvic pathology
• Systemic symptoms: Fever suggests PID or other systemic infection

---

6. Investigations

Bedside Tests

1. Vaginal pH

• Method: pH paper (range 4.0-6.0) on lateral vaginal wall
• Interpretation: pH >4.5 supports BV (also elevated in trichomoniasis, atrophic vaginitis)
• Sensitivity: 97%
• Specificity: 67% (when part of Amsel criteria)

2. Whiff Test (KOH Test)

• Method: Add 10% KOH to vaginal discharge
• Positive: Immediate fishy amine odor
• Sensitivity: 67%
• Specificity: 93%

Clinical Diagnostic Criteria (Amsel Criteria)

Diagnosis requires 3 of 4 criteria: [14]

1. Thin, homogeneous vaginal discharge
2. Clue cells on microscopy (>20% of epithelial cells)
3. Vaginal pH >4.5
4. Positive whiff test (fishy amine odor with KOH)

Sensitivity: 92% | Specificity: 77%

Practical Application:

• Point-of-care diagnosis in clinic/office setting
• Requires microscopy access
• Operator-dependent (experience with microscopy)

Microscopy

Gram Stain (Hay/Ison Criteria) - GOLD STANDARD [15]

Method: Air-dried vaginal smear, Gram stain, oil immersion microscopy

Grading System:

• Grade 1 (Normal): Lactobacillus morphotypes predominantly, normal flora
• Grade 2 (Intermediate): Mixed flora, reduced lactobacilli with some BV-associated bacteria
• Grade 3 (BV): Few or absent lactobacilli, predominantly Gardnerella/Mobiluncus morphotypes, clue cells

Advantages:

• Objective, standardized
• Quantifiable
• Can identify intermediate flora (Grade 2)
• Does not require viable organisms

Disadvantages:

• Requires trained microscopist
• Time-consuming
• Not widely available in primary care

Wet Mount Microscopy

Method: Fresh vaginal discharge in saline on slide

Findings in BV:

• Clue cells: Epithelial cells with borders obscured by adherent bacteria (stippled/granular appearance)
• Absent or rare lactobacilli (large gram-positive rods)
• Coccobacilli: Small gram-variable rods (Gardnerella)
• Mobiluncus: Curved gram-variable rods (if present, indicates severe BV)
• Absent or minimal white blood cells (no inflammatory response)

Clue Cells: Pathognomonic for BV; sensitivity 95%, specificity 85%

Molecular Tests

Nucleic Acid Amplification Tests (NAAT/PCR)

Examples: Affirm VPIII, BD MAX, FemExam

Targets:

• Gardnerella vaginalis
• Atopobium vaginae
• Bacterial Vaginosis-Associated Bacteria (BVAB)
• Lactobacillus quantification

Advantages:

• High sensitivity (>95%)
• High specificity (>95%)
• Rapid results (can be point-of-care)
• Detects organisms not culturable

Disadvantages:

• Expensive
• May over-diagnose (detects G. vaginalis in asymptomatic women)
• Not widely available
• Unclear clinical significance of intermediate results

Sialidase Activity Tests

Method: Rapid enzyme test detecting sialidase produced by BV-associated bacteria

Advantages:

• Point-of-care (results in minutes)
• Good sensitivity (86-90%)
• No microscopy required

Disadvantages:

• Lower specificity than Gram stain
• Not as widely validated

Laboratory Tests (for Specific Indications)

STI Screening (Co-testing Recommended)

BV increases susceptibility to STIs; consider screening for:

• Chlamydia trachomatis (NAAT)
• Neisseria gonorrhoeae (NAAT)
• Trichomonas vaginalis (NAAT or wet mount)
• HIV (if risk factors or patient request)
• Syphilis (serology if indicated)

Other Investigations (if Recurrent/Atypical BV)

• Blood glucose/HbA1c: Screen for diabetes
• HIV test: Immunosuppression associated with recurrent BV
• Thyroid function: If menstrual irregularity
• Vaginal culture: If treatment failure (assess for atypical organisms, Atopobium vaginae)

Diagnostic Algorithm

VAGINAL DISCHARGE ASSESSMENT
            ↓
    HISTORY & EXAMINATION
    (Speculum + pH + Whiff)
            ↓
    ┌───────┴────────┐
   pH >4.5          pH less than 4.5
    ↓                 ↓
Whiff Test        Likely:
    ↓             - Candida
  Positive        - Physiological
    ↓             (Examine for thick
MICROSCOPY         curdy discharge,
 (if available)     erythema)
    ↓
Clue cells >20%?
    ↓
   YES → BV DIAGNOSIS (Amsel 3/4)
    ↓
TREATMENT + STI SCREENING

---

7. Classification and Severity

Hay/Ison Grading (Microbiological Classification)

Clinical Severity (Not Formally Classified)

Mild BV:

• Minimal discharge
• Intermittent odor
• No functional impact
• Grade 2 (intermediate) on microscopy

Moderate BV:

• Noticeable discharge
• Persistent odor (socially bothersome)
• Grade 3 on microscopy
• Standard treatment effective

Severe BV:

• Profuse discharge
• Severe malodorous discharge (significant psychosocial impact)
• Mobiluncus present on microscopy
• Often recurrent
• May require prolonged/suppressive therapy

---

8. Management

Management Algorithm

CONFIRMED BV DIAGNOSIS
        ↓
    SYMPTOMATIC?
  ┌──────┴──────┐
 YES            NO
  ↓              ↓
SPECIAL      PREGNANT? or
SITUATIONS?  PRE-PROCEDURE?
  ↓          ┌─────┴─────┐
             YES         NO
              ↓           ↓
          TREAT      NO TREATMENT
              ↓       (Reassurance)
    ┌─────────┴─────────┐
PREGNANT?         NOT PREGNANT?
    ↓                   ↓
PREGNANCY         FIRST-LINE TREATMENT
REGIMENS          (See below)
    ↓                   ↓
                  FOLLOW-UP 1 MONTH
                        ↓
                  ┌─────┴──────┐
              CURED         RECURRENCE
                 ↓               ↓
            REASSURE      RECURRENT BV
                         MANAGEMENT
                              ↓
                      - Assess compliance
                      - Review risk factors
                      - Prolonged therapy
                      - Suppressive therapy
                      - Specialist referral

First-Line Treatment (Non-Pregnant)

Oral Metronidazole (First Choice)

Regimen: Metronidazole 400-500mg orally twice daily for 5-7 days

Efficacy: 70-80% cure rate at 1 month [16]

Advantages:

• Convenient oral administration
• Well-tolerated
• Cost-effective

Disadvantages/Side Effects:

• Metallic taste (very common, warn patient)
• Nausea, vomiting (take with food)
• Disulfiram-like reaction with alcohol: Severe nausea, vomiting, flushing if alcohol consumed
  • "Patient advice: Avoid alcohol during treatment and for 48 hours after last dose"
• Rare: Peripheral neuropathy (prolonged high-dose use)

Alternative Oral Regimen:

• Metronidazole 2g orally single dose
  • Lower cure rate (~60%), higher recurrence
  • Use only if compliance concern or patient preference

Intravaginal Metronidazole Gel

Regimen: Metronidazole 0.75% gel, one applicator (5g) intravaginally once daily at bedtime for 5 days

Efficacy: 75-85% cure rate (slightly higher than oral) [16]

Advantages:

• Avoids systemic side effects (metallic taste, GI upset)
• High local concentration
• Can consume alcohol (minimal systemic absorption)

Disadvantages:

• Vaginal administration (some women prefer oral)
• Messiness, leakage
• Oil-based: Weakens latex condoms (avoid intercourse or use non-latex barrier during and 3 days after treatment)

Intravaginal Clindamycin

Regimen: Clindamycin 2% cream, one applicator (5g) intravaginally once daily at bedtime for 7 days

Efficacy: 70-80% cure rate [16]

Advantages:

• Alternative if metronidazole contraindicated/not tolerated
• Effective against Gardnerella and anaerobes

Disadvantages:

• Weakens latex condoms for up to 72 hours after treatment (oil-based)
• Risk of pseudomembranous colitis (rare, ~0.01%)
• May cause vaginal candidiasis (10-15%)
• More expensive than metronidazole

Alternative Clindamycin Regimen:

• Clindamycin 300mg orally twice daily for 7 days
  • Higher risk of GI side effects and C. difficile
  • Reserve for special situations

Treatment in Pregnancy

Indications for Treatment

1. Symptomatic BV: Always treat
2. Asymptomatic BV in high-risk women:
   • History of previous preterm birth
   • History of late miscarriage (16-24 weeks)
   • Undergoing gynecological procedure

Controversial: Routine screening of asymptomatic pregnant women is NOT recommended (multiple trials show no reduction in preterm birth with screening and treatment of asymptomatic BV). [11]

Pregnancy-Safe Regimens

Preferred:

• Metronidazole 400mg orally twice daily for 5-7 days
  • Safe in all trimesters (previous first-trimester concerns disproven)

Alternative:

• Clindamycin 300mg orally twice daily for 7 days

Avoid:

• Intravaginal clindamycin (associated with increased adverse pregnancy outcomes in some studies)
• Single-dose metronidazole (insufficient for pregnancy)

Timing: Can treat at any gestation when diagnosed

Management of Recurrent BV

Definition: ≥3 episodes per year or recurrence within 3 months of treatment

Prevalence: 30% recurrence at 3 months, 50-60% at 12 months [12]

Step 1: Assess and Address Risk Factors

• Review compliance: Did patient complete full course?
• Alcohol use during treatment: Caused treatment failure?
• Hygiene practices: Douching? Intravaginal products? Alkaline soaps?
• Sexual practices: New partner? Change in practices?
• Screen for: Diabetes, HIV, immunosuppression

Step 2: Extended Induction Therapy

• Metronidazole 400mg orally twice daily for 10-14 days (longer than standard)
• Or: Metronidazole gel intravaginally for 10 days

Step 3: Suppressive Maintenance Therapy

Regimen: Metronidazole 0.75% gel, one applicator intravaginally twice weekly for 4-6 months

Evidence: Reduces recurrence from 50% to 25% during treatment [12,17]

Considerations:

• Start immediately after completion of induction therapy
• Long-term use appears safe
• Recurrence common after discontinuation
• Patient preference and quality of life important

Step 4: Alternative/Adjunctive Approaches

Probiotics (Lactobacillus Replacement):

• Oral or intravaginal lactobacillus preparations
• Evidence mixed; some benefit shown with L. crispatus strains
• Can be used adjunctively with antibiotics
• Not substitute for antibiotic treatment

Vaginal Acidification:

• Lactic acid gel (Relactagel, Balance Activ)
• Restores acidic pH, creates unfavorable environment for BV-associated bacteria
• Can use after antibiotic treatment or for mild recurrent symptoms
• Limited evidence but safe

Biofilm Disruption (Experimental):

• Research into biofilm-disrupting agents
• Not currently standard of care

Step 5: Specialist Referral

Consider if:

• Persistent symptoms despite multiple treatment courses
• Severe psychosocial impact
• Desire for alternative/experimental therapies
• Atypical presentation

Partner Treatment

Male Partners

Recommendation: Routine treatment of male partners is NOT recommended [5,16]

Evidence: Multiple trials show no benefit in reducing recurrence in female partner

Exceptions: Symptomatic urethritis or balanitis (rare)

Female Partners (WSW)

Recommendation: Screen and treat female partners if symptomatic

Rationale:

• High concordance between female partners
• Transmission appears to occur between women
• Limited evidence but expert opinion supports treatment

Special Situations

Pre-Procedure Treatment

Indications: Treat BV (even if asymptomatic) before:

• Surgical abortion/termination of pregnancy
• Insertion of intrauterine device (IUD)
• Hysterectomy
• Endometrial biopsy
• Hysteroscopy

Rationale: Reduces risk of post-procedural pelvic infection [6]

Timing: Ideally treat 1 week before procedure; can give single dose on day of procedure if necessary

Fertility Treatment

• Treat symptomatic BV before IVF/IUI
• Evidence for treating asymptomatic BV in fertility setting limited
• Individualize based on risk assessment

---

9. Complications

Obstetric Complications

Note: Treating asymptomatic BV in average-risk pregnancy does NOT reduce preterm birth (controversial area)

Gynecological Complications

Increased STI Susceptibility:

• HIV acquisition: 1.5-2× increased risk [18]
  • "Mechanism: Loss of protective lactobacilli, disrupted epithelial barrier, increased HIV target cells"
• HSV-2 acquisition: 1.5-2× increased risk
• Chlamydia/Gonorrhea: Increased susceptibility and transmission
• HPV persistence: May impair viral clearance
• Syphilis: Increased risk of acquisition

Post-Procedural Infections:

• Post-abortion PID: 2-5× increased risk [6]
• Post-hysterectomy vaginal cuff cellulitis: 2-3× increased risk
• Post-IUD insertion PID: Modest increased risk

Psychosocial Impact

• Malodorous discharge causes significant embarrassment and distress
• Impact on sexual relationships and intimacy
• Anxiety about STI implications
• Recurrent BV associated with depression and reduced quality of life

Other Associations

• Urinary tract infections: Possible increased risk
• Cervical intraepithelial neoplasia (CIN): Association described, causality unclear

---

10. Prognosis and Natural History

Without Treatment

• Spontaneous resolution: 30-40% of cases resolve without treatment over 3-6 months
• Persistence: 40-50% remain unchanged
• Progression: 10-20% may worsen

With Treatment

Short-term outcomes (1 month post-treatment):

• Cure rate: 70-85% depending on regimen
• Symptomatic relief: >90%

Long-term outcomes (12 months):

• Recurrence: 50-60% experience at least one recurrence [12]
• Multiple recurrences: 30% experience ≥3 episodes per year
• Persistent symptoms: 10-15% despite multiple treatment courses

Prognostic Factors

Favorable (Lower Recurrence Risk):

• First episode
• COCP use
• Monogamous relationship
• Good compliance with treatment
• Avoidance of douching/intravaginal products

Unfavorable (Higher Recurrence Risk):

• History of multiple previous episodes
• Atopobium vaginae detection (resistant to metronidazole)
• Mobiluncus species present
• Continued douching/intravaginal product use
• New sexual partner
• Smoking
• WSW relationships
• Intermediate Nugent score (Grade 2) after treatment

Long-term Follow-up

• Routine follow-up not necessary if asymptomatic after treatment
• Advise patient to return if symptoms recur
• Test of cure not routinely recommended (unless pregnant)
• Screen for STIs if risk factors

---

11. Prevention and Health Promotion

Primary Prevention

Avoid Vaginal Douching: Strongest modifiable risk factor [13]

• Disrupts normal flora
• Alkalinizes vaginal environment
• Patient education: "The vagina is self-cleaning"

Hygiene Advice:

• Avoid alkaline soaps, perfumed products in genital area
• Use water alone or pH-balanced intimate washes
• Shower preferable to baths (especially bubble baths)
• Wipe front to back
• Change tampons/pads regularly

Sexual Health:

• Condom use (protects from alkaline semen exposure)
• Limit number of sexual partners
• Avoid intravaginal lubricants with glycerin (feeds non-lactobacillus bacteria)

Lifestyle:

• Smoking cessation
• Good diabetes control
• Stress management

Secondary Prevention (Recurrence Prevention)

Post-Treatment Maintenance:

• Metronidazole gel twice weekly for 4-6 months (if recurrent BV)
• Probiotic lactobacillus (adjunctive, evidence limited)
• Vaginal acidifying gels

Behavioral Modifications:

• Stop douching
• Avoid intravaginal products
• Use condoms consistently

Partner Management (WSW):

• Concurrent treatment of symptomatic female partners

---

12. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Hay et al. (BMJ, 1994)

"Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage"

• Established Gram stain (Hay/Ison) criteria
• First major study linking BV to late miscarriage and preterm birth [11]
• Changed practice: BV recognized as obstetric risk factor

2. Swadpanich et al. (Cochrane Review, 2015)

"Antibiotic treatment for bacterial vaginosis in pregnancy"

• Meta-analysis of treatment trials in pregnancy
• Finding: Treating asymptomatic BV in average-risk women does NOT reduce preterm birth
• Changed practice: Routine screening not recommended [11]

3. Bradshaw et al. (Clinical Infectious Diseases, 2006)

"High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy"

• Documented 50-60% 12-month recurrence rate
• Highlighted need for novel approaches to prevent recurrence [12]

4. Sobel et al. (NEJM, 2006)

"Suppressive maintenance therapy with metronidazole gel for recurrent BV"

• Demonstrated efficacy of twice-weekly metronidazole gel
• Established suppressive therapy as management option [17]

5. Atashili et al. (AIDS, 2008)

"Bacterial vaginosis and HIV acquisition: a meta-analysis"

• Confirmed BV increases HIV acquisition risk by 1.5-fold
• Emphasized BV as public health concern in HIV-endemic areas [18]

6. Swidsinski et al. (American Journal of Obstetrics and Gynecology, 2008)

"Adherent biofilms in bacterial vaginosis"

• Demonstrated Gardnerella biofilm structure using FISH microscopy
• Explained persistence and recurrence despite treatment [9]

---

13. Patient and Layperson Explanation

What is Bacterial Vaginosis?

BV is not an infection you "caught" from someone else. It is an imbalance of the natural bacteria that live in the vagina. Think of the vagina as having its own ecosystem, like a garden.

In a healthy vagina, "good bacteria" called Lactobacilli keep the environment clean and acidic (like a well-tended garden). In BV, these good bacteria decline, and "nuisance bacteria" overgrow (like weeds taking over the garden).

Is BV a Sexually Transmitted Infection (STI)?

Not exactly. While BV is more common in sexually active women and can be triggered by sex, it is not passed from person to person like chlamydia or gonorrhea. You cannot "catch" BV from a partner.

However, sexual activity can disrupt the vaginal balance, which is why BV is sometimes called "sexually associated."

Why Does It Smell?

The nuisance bacteria in BV produce chemicals called "amines" (putrescine and cadaverine) that have a strong fishy smell. This smell is often worse after:

• Your period: Blood is alkaline and neutralizes the natural vaginal acid, releasing the smell
• After sex: Semen is alkaline (pH 7.2), which also releases the smell

The smell is not because you are unclean. In fact, the opposite is true...

Can Washing Help?

Overwashing makes BV worse! Using soaps, shower gels, douches, or antiseptics washes away the good bacteria and disrupts the natural balance.

Best practice:

• Wash external genital area only with water or a gentle pH-balanced wash
• Never wash inside the vagina (it's self-cleaning)
• Avoid bubble baths, scented products, and douches
• Showers are better than baths

How Is It Treated?

BV is treated with antibiotics (usually metronidazole tablets or gel) that kill the nuisance bacteria and allow the good bacteria to grow back.

Important:

• Complete the full course even if symptoms go away
• Avoid alcohol if taking metronidazole tablets (causes severe nausea)
• If using the gel, it may weaken condoms (use alternative contraception or abstain)

Does My Partner Need Treatment?

Male partners: No. Treating your male partner does not help prevent BV from coming back.

Female partners (if you have sex with women): Yes. Your female partner should be tested and treated if she has symptoms, as BV can pass between women.

Why Does It Keep Coming Back?

BV comes back in about half of women within a year, even with proper treatment. Reasons include:

• Biofilm: The bacteria create a protective layer that antibiotics can't fully penetrate
• Continued triggers: Douching, smoking, sexual activity disrupting balance
• Individual susceptibility: Some women's vaginal ecosystems are less stable

If you have recurrent BV:

• Your doctor may recommend longer treatment
• Maintenance gel used twice weekly for several months
• Probiotics (good bacteria supplements) may help
• Address triggers: Stop douching, avoid perfumed products

Is BV Dangerous?

For most women, BV is just a nuisance (discharge and smell). However, it can cause problems in certain situations:

If you are pregnant:

• BV slightly increases risk of preterm birth or late miscarriage
• Tell your midwife/doctor if you have symptoms

If you are having gynecological surgery or procedures:

• BV increases risk of infection after surgery (abortion, IUD insertion, hysterectomy)
• You should be treated before the procedure

Sexual health:

• BV makes you slightly more likely to catch STIs (including HIV)
• Use condoms to reduce risk

When Should I See a Doctor?

• First episode: Get checked to confirm diagnosis (not all discharge is BV)
• Pregnant: Always get checked and treated
• Severe symptoms: Affecting your quality of life
• Recurrent BV: Happening >3 times per year
• Not responding to treatment: Symptoms persist after treatment

Self-Care and Prevention

Do:

• Wear cotton underwear
• Use condoms during sex
• Change tampons/pads regularly
• Wipe front to back after toilet
• Take probiotics (may help)

Don't:

• Douche or wash inside vagina
• Use perfumed soaps, bubble baths, or vaginal deodorants
• Smoke (increases BV risk)
• Use oil-based lubricants

---

14. Examination Focus

Common Exam Questions (MRCOG, DFSRH, Medical Finals)

1. "What is bacterial vaginosis?"

Model Answer: "Bacterial vaginosis is a polymicrobial dysbiosis characterized by depletion of lactobacillus-dominant vaginal flora and overgrowth of anaerobic bacteria, particularly Gardnerella vaginalis. It is the most common cause of vaginal discharge in women of reproductive age, affecting approximately 30% of women. Unlike vaginitis, BV is non-inflammatory."

2. "How do you diagnose BV clinically?"

Model Answer: "I would use the Amsel criteria, which require 3 of 4 features:

1. Thin, homogeneous vaginal discharge
2. pH greater than 4.5
3. Positive whiff test (fishy odor with KOH)
4. Clue cells on microscopy (>20%)

The gold standard for laboratory diagnosis is Gram stain using Hay/Ison criteria."

3. "What is a clue cell?"

Model Answer: "A clue cell is a vaginal epithelial cell with borders obscured by adherent bacteria, giving it a stippled or granular appearance. It's pathognomonic for bacterial vaginosis, representing epithelial cells coated in Gardnerella vaginalis biofilm. Clue cells represent >20% of epithelial cells in BV."

4. "How does BV differ from Candida and Trichomonas?"

Model Answer (Use comparison table):

• BV: pH >4.5, thin grey discharge, fishy odor, minimal itch, no inflammation, clue cells
• Candida: pH less than 4.5, thick white discharge, no odor, severe itch, erythema, hyphae
• Trichomonas: pH >4.5, frothy yellow-green discharge, strawberry cervix, motile protozoa, STI requiring partner treatment

5. "What is the first-line treatment for BV?"

Model Answer: "First-line treatment is metronidazole 400mg orally twice daily for 5-7 days, with 70-80% cure rate. Patients must be warned to avoid alcohol during and for 48 hours after treatment due to disulfiram-like reaction. Alternatives include intravaginal metronidazole 0.75% gel for 5 days or intravaginal clindamycin 2% cream for 7 days."

6. "Should you treat the male partner?"

Model Answer: "No. Multiple randomized trials show that routine treatment of male partners does not reduce recurrence in the female partner. However, female partners (in WSW relationships) should be screened and treated if symptomatic due to high concordance."

7. "How do you manage recurrent BV?"

Model Answer: "My approach would be:

1. Assess compliance and review risk factors (douching, smoking)
2. Extended induction therapy: Metronidazole for 10-14 days
3. Suppressive maintenance: Metronidazole gel twice weekly for 4-6 months
4. Consider adjunctive measures: Probiotics, vaginal acidifying gels
5. Specialist referral if persistent despite above measures"

8. "What are the obstetric risks of BV?"

Model Answer: "BV in pregnancy increases risk of:

• Late miscarriage (16-24 weeks): 2-3 fold
• Preterm birth: 1.5-2 fold
• PPROM: 2-3 fold
• Chorioamnionitis and postpartum endometritis

However, Cochrane review shows that screening and treating asymptomatic BV in average-risk women does NOT reduce preterm birth, so routine screening is not recommended."

9. "Why does BV increase HIV risk?"

Model Answer: "BV increases HIV acquisition by 1.5-2 fold through several mechanisms:

1. Loss of protective lactobacilli that produce lactic acid and H₂O₂
2. Disrupted epithelial barrier allowing viral entry
3. Increased HIV target cells (CD4+ T cells, macrophages) in vaginal mucosa
4. Elevated inflammatory mediators despite absence of overt inflammation This has significant public health implications in HIV-endemic regions."

10. "What is the biofilm hypothesis in BV recurrence?"

Model Answer: "Gardnerella vaginalis forms a structured biofilm on vaginal epithelium, creating a bacterial community encased in extracellular matrix. This biofilm:

1. Acts as physical barrier to antibiotic penetration
2. Protects bacteria from host immune clearance
3. Serves as reservoir for rapid recurrence after treatment
4. Explains the 50-60% recurrence rate at 12 months despite appropriate antibiotic therapy

Current research focuses on biofilm-disrupting strategies to improve cure rates."

Viva Points

Viva Point: Opening Statement: "Bacterial vaginosis is a polymicrobial vaginal dysbiosis affecting approximately 30% of women of reproductive age. It's characterized by replacement of lactobacillus-dominant flora with anaerobic bacteria, particularly Gardnerella vaginalis, resulting in characteristic thin grey discharge with fishy odor."

Must-Know Statistics:

• Prevalence: 30% of reproductive-age women
• Recurrence: 50-60% at 12 months
• Pregnancy risks: 2× preterm birth, 3× late miscarriage
• HIV risk: 1.5-2× increased acquisition

Key Classifications to Quote:

• Amsel Criteria (3 of 4): Discharge, pH >4.5, whiff test, clue cells
• Hay/Ison Grading: Grade 1 (normal), Grade 2 (intermediate), Grade 3 (BV)

Treatment Pearls:

• Metronidazole 400mg BD for 5-7 days (warn about alcohol)
• Recurrent BV: Suppressive gel twice weekly for 4-6 months
• Partner treatment: Not for males; consider for females (WSW)

Don't Forget:

• Screen before gynecological procedures (abortion, IUD, hysterectomy)
• Treat symptomatic pregnant women (but screening asymptomatic low-risk women not beneficial)
• Always offer STI screening (BV increases STI susceptibility)

Common Mistakes (What Fails Candidates)

❌ Calling BV an STI: It's sexually associated, not transmitted ❌ Recommending partner treatment for males: No evidence of benefit ❌ Prescribing metronidazole without alcohol warning: Disulfiram reaction is severe ❌ Confusing pH values: BV pH >4.5; Candida pH less than 4.5 ❌ Recommending douching: This causes BV, not treats it ❌ Routine screening of asymptomatic pregnant women: Not evidence-based ❌ Missing clue cells on microscopy: Pathognomonic for BV ❌ Forgetting STI co-testing: BV increases STI risk

---

15. References

1. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-523. doi:10.1016/j.ajog.2013.05.006

2. Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304-311. doi:10.1097/OLQ.0000000000000972

3. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod. 2001;16(9):1809-1813. doi:10.1093/humrep/16.9.1809

4. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899-1911. doi:10.1056/NEJMoa043802

5. Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214(Suppl 1):S1-S5. doi:10.1093/infdis/jiw121

6. Larsson PG, Platz-Christensen JJ, Thejls H, et al. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol. 1992;166(1 Pt 1):100-103. doi:10.1016/0002-9378(92)91839-7

7. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol. 1990;75(1):52-58.

8. Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis. 2014;210(3):338-343. doi:10.1093/infdis/jiu089

9. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013-1023. doi:10.1097/01.AOG.0000183594.45524.d2

10. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869. doi:10.1097/OLQ.0b013e318074e565

11. Hay PE, Lamont RF, Taylor-Robinson D, et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994;308(6924):295-298. doi:10.1136/bmj.308.6924.295

12. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-1486. doi:10.1086/503780

13. Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am J Epidemiol. 2008;168(2):188-196. doi:10.1093/aje/kwn103

14. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9

15. Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect. 2002;78(6):413-415. doi:10.1136/sti.78.6.413

16. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1

17. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283-1289. doi:10.1016/j.ajog.2005.11.041

18. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22(12):1493-1501. doi:10.1097/QAD.0b013e3283021a37

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists and use clinical judgment.